Asarina Pharma

In recent months, the Company and its financial advisor have reached out to a broad group of potential partners. As of the middle of November, the Company has a number of on-going dialogues with companies which have expressed interest in Sepranolone.

It is not clear when these dialogues will come to a conclusion and there is no certainty that a partnership can be established on satisfactory terms.

In parallel, the Company has implemented significant savings, primarily by reducing staff costs. Furthermore, the Company has obtained a convertible loan of SEK 1 million from its major shareholder. This means that Asarina has the necessary financial resources to conduct the current partnering activities.

Peter Nordkild, CEO: “We knew that finding a partner for Sepranolone would take time. We are hopeful that we will eventually find a partner who can contribute to bringing Sepranolone further on in its clinical development. In the meantime, we have taken measures to strengthen our financial capability.”